tiprankstipranks
NeuroSense Therapeutics Reports Mid-Year Financials
Company Announcements

NeuroSense Therapeutics Reports Mid-Year Financials

Neurosense Therapeutics Ltd. (NRSN) has released an update.

Pick the best stocks and maximize your portfolio:

NeuroSense Therapeutics Ltd. has reported a decrease in total assets from $3,185,000 to $1,841,000 within the first half of 2024, reflecting a significant drop in cash and cash equivalents. The company’s net loss widened to $6,261,000 for the six months ended June 30, 2024, compared to the same period in the previous year. Despite a challenging period, NeuroSense continued to raise capital through the issuance of shares, bringing in a net amount of $4,209,000.

For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment
TheFlyNeuroSense concludes Type C meeting with FDA for PrimeC treatment
TheFlyNeuroSense files to sell 6.6M ordinary shares for holders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App